MET Targeted Therapy for NSCLC
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
FDA Grants Final Approval to Cabozantinib Capsule Formulation
3
Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care
4
Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma
5